Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

DIVE INTO DIALYSIS: NxStage Aims To Transform Home Hemodialysis Into $2bn Market

This article was originally published in Clinica

  • News

Executive Summary

For the second part of Clinica’s three-part special series on the dialysis market, Reed Miller talked to the CEO of NxStage Medical, a Massachusetts-based company that markets the NxStage System One, which the firm touts as the only “truly portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis. As the company is set to face competition for home hemodialysis customers from upstarts like Quanta, profiled in part 1 of this series, and giants like Fresenius Medical Care, the subject of part 3, NxStage is planning to use home hemodialysis as a “beachhead” to invade other, more lucrative markets

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT103048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By